Wall Street is positive on PDS Biotechnology Corp (PDSB). On average, analysts give the stock a Strong Buy rating. The average price target is $6.483, which means analysts expect the stock to add by 159.32% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 63, which is better than 63% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With PDS Biotechnology Corp Stock Today?
PDS Biotechnology Corp (PDSB) stock is up 11.45% while the S&P 500 is flat 0% as of 10:57 AM on Friday, Sep 25. PDSB has risen $0.26 from the previous closing price of $2.24 on volume of 149,353 shares. Over the past year the S&P 500 is higher by 9.03% while PDSB is lower by -27.11%. PDSB lost -$2.46 per share the over the last 12 months.
Click Here to get the full report on PDS Biotechnology Corp (PDSB) Stock.
